+ND Capital (formerly NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences, focusing on opportunities driven by scientific convergence. The firm is headquartered in Woodside, California with offices in Switzerland.
42% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Average disclosed round size is $44.8M (across 38 rounds with reported amounts).
Portfolio
31
Fund Size
$800M
Top Stage
Series A
Last 12 Mo
1
Team
Alison Palmer
Vice President of the General Partner
Jonathan Nicholson
Executive Director of the General Partner
Richard Coles
Director of the General Partner
Klaus Dugi
Chief Medical Advisor & Venture Partner
Luc Bauer
Venture Partner
Peter Van Vlasselaer
Venture Partner
Ryan Schubert
Venture Partner
Kirill Kuzmichev
Principal
Aymeric Sallin
Founder & Chief Executive Officer
Cathleen O’Connor
Executive Assistant
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Spark Microsystems | Series B | $17M | Mar 2026 |
 Lightcast | Unknown | $27M | Jan 2026 |
 Visby Medical | Growth | $55M | Jun 2025 |
| VVisby | Series E | $65M | Jun 2025 |
 Haya Therapeutics | Series A | $65M | May 2025 |
 Constructive Bio | Series A | $58M | Sep 2024 |
 Vandria | Series A | — | Aug 2024 |
| Vandria | Seed | — | Mar 2024 |
| PPartillion | Seed | $5M | Sep 2023 |
 Lightcast Discovery | Series B | $49M | Aug 2023 |
 Lightcast | Unknown | $38M | Aug 2023 |
| Lightcast | Series B | $38M | Jan 2023 |
| VVisby | Series E | $100M | Jun 2022 |
| Visby Medical | Series E | $135M | Jun 2022 |
 Emulate | Series E | $82M | Sep 2021 |
 Cytoki Pharma | Series A | $45M | May 2021 |
 Sorbet | Seed | $6M | Apr 2021 |
| Cytoki Pharma | Series A | $45M | Jan 2021 |
 IonPath | Series B | $18M | Sep 2020 |
 Alveo Energy | Series D | $35M | Jul 2020 |
 SiMa.ai | Series A | $30M | May 2020 |
| Alveo Energy | Unknown | $13.7M | Nov 2019 |
| AAmphivena Therapeutics | Series C | $62M | Sep 2019 |
 Amphivena | Series C | $62M | Sep 2019 |
 Icosavax | Series A | $51M | Jan 2019 |
Top Co-Investors
Last updated: 7 October 2026